申请人:Neurogen Corporation
公开号:US06034252A1
公开(公告)日:2000-03-07
Disclosed are compounds of the formula: ##STR1## or the pharmaceutically acceptable salts thereof wherein wherein: R.sub.1, R.sub.2, and and R.sub.4 independenlty represent hydrogen, halogen, alkyl, cyano, alkoxycarbonyl, trifluoromethoxy, SO.sub.2 NH.sub.2 or trifluoromethyl; R.sub.3 represents hydrogen, halogen, alkyl, alkoxy, alkylthio, hydroxy, amino, mono- or di(C.sub.1 -C.sub.6)alkylamino, cyano, alkoxycarbonyl, trifluoromethoxy, SO.sub.2 NH.sub.2 or trifluoromethyl; or R.sub.3 represents optionally substituted phenyl; X represents (CH.sub.2).sub.n where n is an integer; and m is 0 or an integer, which compounds are useful for the treatment and/or prevention of neuropsychological disorders including, but not limited to, schizophrenia, mania, dementia, depression, anxiety, compulsive behavior, substance abuse, Parkinson-like motor disorders and motion disorders related to the use of neuroleptic agents.
揭示的化合物的化学式如下:##STR1##或其药学上可接受的盐,其中:R.sub.1、R.sub.2和R.sub.4独立地代表氢、卤素、烷基、氰基、烷氧羰基、三氟甲氧基、SO.sub.2 NH.sub.2或三氟甲基;R.sub.3代表氢、卤素、烷基、烷氧基、烷基硫醚、羟基、氨基、单取代或双(C.sub.1-C.sub.6)烷基氨基、氰基、烷氧羰基、三氟甲氧基、SO.sub.2 NH.sub.2或三氟甲基;或R.sub.3代表可选择取代的苯基;X代表(CH.sub.2).sub.n,其中n是整数;m为0或整数,这些化合物用于治疗和/或预防神经心理障碍,包括但不限于精神分裂症、躁狂症、痴呆、抑郁症、焦虑症、强迫行为、物质滥用、帕金森病样运动障碍和与神经阻滞剂使用相关的运动障碍。